Skip to main content
Fig. 5 | Biomarker Research

Fig. 5

From: Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis

Fig. 5

Survival analysis. a Duration of response in all 60 patients with advanced HCC who received first-line lenvatinib plus anti-PD-1 antibodies. b Duration of response in MVTT (n = 18; Note: these are the 18 patients who achieved a response to therapy) and intrahepatic tumors (n = 19) (P = 0.143). c, d Progression-free survival and overall survival in all 60 patients. e Overall survival among patients with MVTT and intrahepatic tumors (n = 33) who did and did not achieve a treatment response in MVTT (P = 0.037). f Overall survival among patients with intrahepatic tumors (n = 58) who did and did not achieve a response to treatment (P = 0.198)

Back to article page